What Is Alzheimer’s Disease? The Definitive Answer

Alzheimer’s disease is a progressive, irreversible neurodegenerative disorder that gradually destroys memory, cognitive function, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia — accounting for between 60% and 80% of all dementia diagnoses globally — and it represents the sixth leading cause of death in the United States, according to the Alzheimer’s Association’s annual Facts and Figures report.

The disease was first described in 1906 by German psychiatrist and neuropathologist Alois Alzheimer, who observed unusual brain abnormalities during the postmortem examination of a 50-year-old woman named Auguste Deter. When Alzheimer examined her brain tissue under a microscope, he found what we now recognize as the two cardinal hallmarks of the disease: amyloid plaques (then called “senile plaques”) and neurofibrillary tangles made of twisted fibers inside neurons.

What Is the Difference Between Alzheimer’s Disease and Dementia?

This distinction appears on almost every introductory neuroscience and gerontology exam. Dementia is not a specific disease — it’s a syndrome, a cluster of symptoms including memory loss, impaired reasoning, personality changes, and difficulty with language that are severe enough to interfere with daily life. Alzheimer’s disease is the most common specific disease that causes dementia. Other diseases that cause dementia include vascular dementia, Lewy body dementia, and frontotemporal dementia.

The practical consequence: all Alzheimer’s patients have dementia, but not all dementia is Alzheimer’s. This distinction matters clinically for treatment, and academically because homework questions frequently test whether students can distinguish the general category from the specific disease.

How Does Alzheimer’s Disease Progress Over Time?

Alzheimer’s follows a predictable trajectory across three broad stages:

• Mild (early-stage) Alzheimer’s: The person may still function independently. Symptoms include difficulty remembering recent events, names, or conversations; trouble with complex planning; and occasionally getting lost. The disease has often been active biologically for 10–20 years before symptoms appear.
• Moderate (middle-stage) Alzheimer’s: This is typically the longest stage. Memory loss worsens significantly — the person may forget their own history, fail to recognize family members, or become confused about dates and location. Behavioral changes including agitation and wandering often emerge.
• Severe (late-stage) Alzheimer’s: The individual loses the ability to communicate verbally, becomes completely dependent for all care, and is highly vulnerable to infections, particularly pneumonia, which is a common cause of death.

For finer clinical granularity, the Global Deterioration Scale (Reisberg Scale) breaks progression into seven stages, and the Clinical Dementia Rating (CDR) scale is widely used in research settings.

The Brain Pathology of Alzheimer’s: Plaques, Tangles, and Neurodegeneration

The disease’s physical signature in brain tissue consists of two hallmark abnormalities — amyloid plaques and neurofibrillary tangles — combined with profound neuronal loss, synaptic failure, and neuroinflammation. Grasping exactly what these are, where they come from, and how they damage the brain is the foundation of everything else in your Alzheimer’s homework.

What Are Amyloid Plaques and Why Are They Harmful?

Amyloid plaques are abnormal deposits of a protein fragment called amyloid-beta (Aβ) that accumulate in the spaces between neurons. In Alzheimer’s disease, the enzyme beta-secretase (BACE1) cuts APP instead of alpha-secretase, producing amyloid-beta fragments — particularly the 42-amino acid form (Aβ42) — that form toxic oligomers and eventually insoluble plaques.

The amyloid cascade hypothesis, first proposed by John Hardy and Gerald Higgins in 1992, argues that Aβ accumulation is the initiating event that triggers the entire neurodegenerative cascade: synaptic dysfunction, tau pathology, neuroinflammation, and ultimately neuronal death. This hypothesis underpins the recent anti-amyloid drugs lecanemab (Leqembi) and donanemab.

What Are Neurofibrillary Tangles?

Neurofibrillary tangles (NFTs) are abnormal accumulations of a protein called tau that build up inside neurons. In healthy neurons, tau stabilizes microtubules — the structural “highways” that transport nutrients along axons. In Alzheimer’s disease, tau becomes abnormally hyperphosphorylated, detaches from microtubules, and aggregates into insoluble tangles. The consequence is devastating: microtubules collapse, axonal transport breaks down, and the neuron eventually dies.

Tau pathology spreads through the brain in a predictable anatomical pattern described by the Braak and Braak staging system (1991): tangles first appear in the entorhinal cortex (Braak stages I–II), then spread to the hippocampal region (stages III–IV), then the neocortex (stages V–VI). This explains why episodic memory fails first.

What Parts of the Brain Does Alzheimer’s Affect?

Alzheimer’s begins in the entorhinal cortex and hippocampus. As pathology spreads to the temporal and parietal lobes, language difficulties and spatial disorientation emerge. When frontal lobe involvement increases, personality changes and executive dysfunction become prominent. In late stages, damage reaches the brainstem, disrupting basic bodily functions.

Brain atrophy is measurable by MRI. In Alzheimer’s, the hippocampus shrinks at approximately 3–6% per year, compared to less than 1% in healthy aging. The brain as a whole can lose 10–15% of its total weight in severe Alzheimer’s.

The Role of Neuroinflammation

Microglia, the brain’s resident immune cells, are chronically activated in Alzheimer’s. Prolonged activation releases inflammatory cytokines (including IL-1β, TNF-α, and IL-6) that damage surrounding neurons. Recent GWAS have identified multiple Alzheimer’s risk genes — including TREM2, CR1, and CLU — that directly implicate microglial function, suggesting neuroinflammation may be a primary driver, not merely secondary damage.

Genetics of Alzheimer’s Disease: APOE, APP, and Familial Risk

Distinguishing between familial early-onset Alzheimer’s and the much more common sporadic late-onset form — and understanding the genetic architecture of each — is essential for most bioscience and medical coursework.

Early-Onset Familial Alzheimer’s Disease (EOFAD)

Approximately 1–5% of Alzheimer’s cases are caused by rare, highly penetrant mutations in three genes: APP (amyloid precursor protein, chromosome 21), PSEN1 (presenilin 1, chromosome 14), and PSEN2 (presenilin 2, chromosome 1). These mutations follow an autosomal dominant inheritance pattern, and individuals carrying them typically develop Alzheimer’s before age 65 — sometimes as early as their 30s or 40s.

The Down syndrome connection is notable: individuals with Down syndrome carry three copies of chromosome 21 (which contains the APP gene), and virtually all develop Alzheimer’s pathology by their 40s — a natural genetic experiment that powerfully supports the amyloid hypothesis.

APOE ε4: The Major Risk Gene for Late-Onset Alzheimer’s

The APOE gene exists in three common allele forms: ε2, ε3, and ε4. APOE ε4 is by far the strongest known genetic risk factor for late-onset Alzheimer’s disease. Carrying one copy increases risk approximately 3-fold; carrying two copies increases risk approximately 8–12-fold. APOE protein is involved in amyloid-beta clearance — the ε4 isoform is less efficient at clearing amyloid-beta from the brain, contributing to plaque accumulation. Despite this strong association, APOE ε4 is neither necessary nor sufficient to cause Alzheimer’s.

Beyond APOE: Genome-Wide Association Studies and Polygenic Risk

GWAS have identified more than 80 genetic loci associated with Alzheimer’s risk beyond APOE. Particularly notable genes include BIN1, CLU (clusterin), CR1 (complement receptor 1), PICALM, and TREM2. Their combined effect in a polygenic risk score (PRS) can meaningfully stratify population risk.

How Is Alzheimer’s Disease Diagnosed? Criteria, Tools, and Biomarkers

Diagnosing Alzheimer’s disease is considerably more complex than diagnosing most medical conditions — there is no simple blood test, no uniquely diagnostic imaging finding, and for most of the disease’s history, a definitive diagnosis required postmortem brain examination.

The NIA-AA Diagnostic Criteria

The current standard diagnostic framework is the NIA-AA criteria (National Institute on Aging — Alzheimer’s Association), updated most recently in 2024. These criteria introduced a biological/biomarker-based definition using an A/T/N classification system: A = Amyloid biomarkers, T = Tau biomarkers, N = Neurodegeneration/neuronal injury markers. A positive amyloid biomarker (A+) is required for a biological diagnosis of Alzheimer’s disease, regardless of whether cognitive symptoms are present. This represents a paradigm shift — Alzheimer’s is now conceptualized as a biological entity with a long preclinical phase (sometimes 15–20 years before symptoms appear).

Cognitive Assessment Tools

• Mini-Mental State Examination (MMSE): A 30-point test assessing orientation, registration, attention, recall, language, and visuospatial ability. Scores of 24–30 are considered normal; 20–23 suggests mild impairment; 10–19 moderate; <10 severe.
• Montreal Cognitive Assessment (MoCA): A 30-point assessment generally considered more sensitive than the MMSE for detecting mild cognitive impairment (MCI), developed by Ziad Nasreddine in Montreal.
• Alzheimer’s Disease Assessment Scale — Cognitive Subscale (ADAS-Cog): The most widely used cognitive outcome measure in Alzheimer’s clinical trials.
• Clinical Dementia Rating (CDR): A global staging tool assessing memory, orientation, judgment, community affairs, home/hobbies, and personal care.

Neuroimaging in Alzheimer’s Diagnosis

MRI detects hippocampal and cortical atrophy and rules out other causes of cognitive decline. FDG-PET shows reduced glucose metabolism in the temporoparietal and posterior cingulate cortices. Amyloid PET imaging directly visualizes amyloid plaque burden in the living brain. Tau PET (flortaucipir/Tauvid, FDA-approved 2020) visualizes tau tangle burden and correlates more closely with cognitive symptoms than amyloid burden alone.

Blood-Based Biomarkers: The Frontier of Alzheimer’s Diagnosis

The plasma phospho-tau 217 (p-tau217) assay has shown particularly strong diagnostic accuracy, with sensitivity and specificity approaching CSF tests in some studies. The FDA cleared the first blood test (Lumipulse plasma Aβ42/40) for Alzheimer’s evaluation in 2024 — a major milestone that makes diagnosis far more accessible and scalable globally.

Alzheimer’s Disease Treatment: Current Therapies and Emerging Drugs

The honest and academically important framing is that no treatment currently available can stop or reverse Alzheimer’s disease. All approved therapies are either symptomatic (improving function without addressing the underlying disease process) or, in the newest case, disease-modifying in the sense of slowing progression — not halting it.

Cholinesterase Inhibitors: The Cholinergic Hypothesis in Clinical Practice

The three acetylcholinesterase inhibitors (AChEIs) — donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne) — are rooted in the cholinergic hypothesis. This hypothesis proposes that Alzheimer’s cognitive deficits result primarily from degeneration of cholinergic neurons in the nucleus basalis of Meynert. These neurons release acetylcholine (ACh), critical for learning and memory. AChEIs block the enzyme acetylcholinesterase that breaks down ACh, prolonging cholinergic function. Donepezil is approved for all stages; rivastigmine and galantamine for mild-to-moderate stages.

Memantine: NMDA Receptor Antagonism

Memantine (Namenda), approved by the FDA in 2003, is an NMDA receptor antagonist. In Alzheimer’s, pathological overactivation of NMDA receptors by glutamate causes excessive calcium influx into neurons and contributes to neuronal damage. Memantine partially blocks these receptors, reducing excitotoxic damage. It is approved for moderate-to-severe Alzheimer’s and is often used in combination with donepezil.

Anti-Amyloid Immunotherapy: The Game-Changing New Treatments

Lecanemab (Leqembi) — developed by Eisai and Biogen — received full FDA approval in 2023 based on the Phase 3 CLARITY-AD trial, demonstrating a 27% slowing of cognitive decline over 18 months. Donanemab (Kisunla), developed by Eli Lilly, received FDA approval in July 2024, showing a 35% slowing of cognitive decline in the TRAILBLAZER-ALZ 2 trial. Both drugs carry risks of ARIA (Amyloid-Related Imaging Abnormalities) — brain swelling and microhemorrhages — requiring regular MRI monitoring.

Non-Pharmacological Approaches

Beyond medication, Cognitive stimulation therapy (CST) is recommended by NICE in the UK as a first-line intervention for mild-to-moderate dementia. Exercise programs, music therapy, and occupational therapy also have supporting evidence for improving wellbeing and maintaining function in Alzheimer’s disease.

Alzheimer’s Disease Risk Factors: What Increases and What Reduces Risk

Non-Modifiable Risk Factors

Age is the single greatest risk factor: prevalence roughly doubles every five years after age 65. Family history and genetics (especially APOE ε4) are non-modifiable. Sex is another factor — women have a higher lifetime risk than men (approximately 1 in 5 women vs. 1 in 10 men). Down syndrome substantially elevates risk due to an extra copy of the APP gene, and head trauma with loss of consciousness is associated with increased risk.

Modifiable Risk Factors and Prevention

The 2024 Lancet Commission on Dementia Prevention, Intervention, and Care identified 14 modifiable risk factors that together account for approximately 45% of all dementia cases globally: lower education in early life, hearing loss, depression, social isolation, physical inactivity, high blood pressure, diabetes, obesity, smoking, excessive alcohol consumption, traumatic brain injury, air pollution, high LDL cholesterol, and untreated vision loss.

The FINGER trial in Finland demonstrated that a multidomain lifestyle intervention slowed cognitive decline in at-risk older adults — providing the first large randomized evidence for lifestyle-based prevention. The SPRINT MIND trial showed that treating blood pressure significantly reduced mild cognitive impairment incidence.

The MIND and Mediterranean Diets in Alzheimer’s Risk Reduction

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay), developed specifically for brain health by Martha Clare Morris at Rush University Medical Center, emphasizes leafy green vegetables, berries, nuts, beans, whole grains, fish, poultry, and olive oil. Observational studies found high adherence was associated with cognitive performance equivalent to being 7.5 years cognitively younger. A large randomized controlled trial (MIND-AD) is underway to test this more rigorously.

Alzheimer’s Caregiving: Burden, Support Systems, and Ethical Challenges

The Scale of Alzheimer’s Caregiving in the US and UK

According to the Alzheimer’s Association, approximately 11.5 million Americans provided unpaid care to someone with Alzheimer’s or another dementia in 2023 — contributing an estimated 18.4 billion hours of care valued at over $346 billion. Studies consistently find elevated rates of depression, anxiety, social isolation, and physical health problems among Alzheimer’s caregivers. Caregiver burden is measurable using validated tools like the Zarit Burden Interview and the Caregiver Strain Index.

In the United Kingdom, the Alzheimer’s Society estimates that 700,000 people are currently providing unpaid dementia care, with the total economic value exceeding £18 billion annually. The Carers Act 2014 in England gave unpaid carers a legal right to a needs assessment and support from local authorities.

Ethical Dilemmas in Alzheimer’s Care

• Autonomy and decision-making capacity: As cognitive impairment progresses, Alzheimer’s patients lose the capacity to make informed decisions. Advance directives and lasting powers of attorney are the primary legal tools, but they are imperfect.
• Disclosure of diagnosis: In most Western healthcare systems, disclosure is considered standard ethical practice — the person has a right to know their diagnosis, though timing and sensitivity are critical.
• Use of restraints and sedation: Antipsychotic medications carry serious risks in dementia patients, including increased mortality, raising ethical questions about safety vs. dignity.
• End-of-life care decisions: Alzheimer’s raises profound questions about artificial nutrition and hydration in late stages, and the use of antibiotics to treat life-threatening infections when preferences can no longer be expressed.
• Research participation: Enrolling cognitively impaired individuals in clinical trials requires surrogate consent — ensuring this is truly in the individual’s interest.

These ethical challenges are analyzed through frameworks of principlism (Beauchamp and Childress’s four principles: autonomy, beneficence, non-maleficence, justice) and virtue ethics.

Memory Care Units and Dementia Villages

In the Netherlands, the innovative Hogeweyk (“Dementia Village”) in Weesp is a purpose-built village where residents live in small group homes and can freely move around a simulated town. These models reflect the person-centered care philosophy championed by Tom Kitwood in his landmark 1997 work Dementia Reconsidered, which argued for recognizing and supporting “personhood” in dementia care regardless of cognitive decline.

Current Alzheimer’s Research: Biomarkers, Trials, and Future Directions

The Alzheimer’s Disease Neuroimaging Initiative (ADNI)

The ADNI, launched in 2004 and funded by the National Institute on Aging, has enrolled over 2,000 participants following them longitudinally with clinical assessments, MRI, PET imaging, blood and CSF biomarkers, and genetic testing. ADNI data are openly shared with qualified researchers globally, contributing to hundreds of peer-reviewed publications and underpinning most current understanding of Alzheimer’s biomarker trajectories.

The Amyloid Cascade Hypothesis: Successes and Controversies

A notable controversy emerged in 2022 when a Science investigation revealed potential data manipulation in a highly cited 2006 paper by Sylvain Lesné at the University of Minnesota, which had been cited over 2,300 times. This prompted reassessment of parts of the amyloid evidence base, though it did not undermine the broader scientific consensus supporting amyloid’s central role. Awareness of this controversy signals academic sophistication in any Alzheimer’s assignment.

Beyond Amyloid: The Tau-First Hypothesis and Other Targets

Multiple research programs are targeting pathways beyond amyloid. Anti-tau therapies include tau aggregation inhibitors, anti-tau vaccines, and antisense oligonucleotides (ASOs) in Phase 2/3 trials. Given that tau tangle burden correlates more closely with cognitive symptoms than amyloid burden, many researchers argue tau is the more clinically relevant target.

Common Alzheimer’s Disease Homework Questions and How to Answer Them

Explaining the Amyloid Cascade Hypothesis

A strong answer does three things: accurately describes the hypothesis (APP processing → Aβ production → oligomer formation → plaque deposition → tau hyperphosphorylation → neuroinflammation → synaptic dysfunction and neuronal death); presents the key evidence supporting it (EOFAD genetics, Down syndrome, amyloid PET findings, anti-amyloid drug effects); and presents the main criticisms (late-stage trial failures, modest effect sizes of approved drugs, the Lesné research controversy, and the alternative tau-first hypothesis). A one-sided answer is always weaker than a nuanced one that engages with both evidence and critique.

Comparing Early-Onset and Late-Onset Alzheimer’s

Key dimensions for comparison: age of onset (before 65 vs. after 65), genetic mechanism (dominant mutations in APP/PSEN1/PSEN2 vs. risk alleles with APOE ε4 and polygenic background), proportion of cases affected (1–5% vs. 95–99%), pathological similarities (both show amyloid plaques and tau tangles), and clinical presentation (EOFAD may have more atypical presentations). Clearly structuring this comparison using a framework of similarities and differences demonstrates sophisticated understanding.

Analyzing Alzheimer’s Care from a Nursing Perspective

Alzheimer’s Disease vs. Other Dementias: Key Distinctions for Your Homework

Alzheimer’s Disease vs. Vascular Dementia

Vascular dementia is the second most common cause of dementia (approximately 15–20% of cases). Key distinguishing features include a more stepwise (rather than gradual) cognitive decline; prominent executive dysfunction and slowed processing speed relative to memory impairment; and neuroimaging showing cerebrovascular disease rather than primarily hippocampal atrophy. Mixed dementia — Alzheimer’s pathology coexisting with cerebrovascular disease — is extremely common and may be the most prevalent form of dementia in older adults.

Alzheimer’s Disease vs. Lewy Body Dementia

Dementia with Lewy bodies (DLB) presents with a distinctive clinical picture: fluctuating cognition, visual hallucinations (typically vivid and detailed), and parkinsonism. Crucially, DLB patients are extremely sensitive to conventional antipsychotic medications, which can trigger severe and potentially fatal neuroleptic sensitivity reactions — a clinically critical distinction for nursing and medical students.

Alzheimer’s Disease vs. Frontotemporal Dementia

Frontotemporal dementia (FTD) typically presents in people aged 45–65, producing behavioral changes, personality changes, and language difficulties as the dominant early features — with relative sparing of episodic memory early in the disease. This contrasts sharply with Alzheimer’s, where memory loss is the cardinal early symptom.

Mild Cognitive Impairment (MCI): The Transitional State

Mild Cognitive Impairment (MCI) occupies the clinical space between normal aging and dementia — measurable cognitive impairment beyond age expectations but with retained independence in daily functioning. Amnestic MCI progresses to Alzheimer’s at approximately 10–15% per year. MCI is now the primary target population for clinical trials of disease-modifying Alzheimer’s therapies.

Frequently Asked Questions: Alzheimer’s Disease Homework